Promoter hypermethylation and downregulation of trefoil factor 2 in human gastric cancer

Jiang,Ping; Yu,Guoyu; Zhang,Yong; Xiang,Yang; Zhu,Zhu; Feng,Weiyang; Lee,Wenhui; Zhang,Yun

doi:10.3892/ol.2014.1904

Promoter hypermethylation and downregulation of trefoil factor 2 in human gastric cancer

Authors:
- Ping Jiang
- Guoyu Yu
- Yong Zhang
- Yang Xiang
- Zhu Zhu
- Weiyang Feng
- Wenhui Lee
- Yun Zhang
View Affiliations

Affiliations: Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, P.R. China, Department of Gastroenterology, The First Affiliated Hospital of Kunming Medical University, Kunming,Yunnan 650032, P.R. China, Department of Biochemistry, Kunming Medical University, Kunming, Yunnan 650500, P.R. China
Published online on: February 21, 2014 https://doi.org/10.3892/ol.2014.1904
Pages: 1525-1531

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Trefoil factor 2 (TFF2) plays a protective role in gastric mucosa and may be involved in the progression of gastric cancer, but the detailed functions and underlying molecular mechanisms are not clear. The present study used a combination of clinical observations and molecular methods to investigate the correlation between abnormal expression of TFF2 and gastric cancer progression. TFF2 expression was evaluated by reverse transcription polymerase chain reaction (RT-PCR), quantitative PCR (qPCR), and western blot and immunohistochemistry analyses. TFF2 methylation levels were analyzed by genomic bisulfite sequencing method. The results showed that TFF2 mRNA and protein expression were decreased in gastric cancer tissues compared with the matched non‑cancerous mucosa, and the decreased level was associated with the differentiation and invasion of gastric cancer. Moreover, the average TFF2 methylation level of CpG sites in the promoter region was 70.4% in three gastric cancer tissues, while the level in associated non‑neoplastic tissues was 41.0%. Furthermore, the promoter hypermethylation of TFF2 was also found in gastric cancer cell lines, AGS and N87, and gene expression was significantly increased following treatment with a demethylating agent, 5‑Aza‑2'‑deoxycytidine. In conclusion, TFF2 expression was markedly decreased in gastric cancer and promoter hypermethylation was found to regulate the downregulation of TFF2. TFF2 has been suggested as a tumor suppressor in gastric carcinogenesis and metastasis.

View Figures

View References

1	Correa P: Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 52:6735–6740. 1992.
2	Sands BE and Podolsky DK: The trefoil peptide family. Annu Rev Physiol. 58:253–273. 1996. View Article : Google Scholar
3	Thim L: Trefoil peptides: from structure to function. Cell Mol Life Sci. 53:888–903. 1997. View Article : Google Scholar : PubMed/NCBI
4	Fox JG, Rogers AB, Whary MT, et al: Accelerated progression of gastritis to dysplasia in the pyloric antrum of TFF2 −/− C57BL6 x Sv129 Helicobacter pylori-infected mice. Am J Pathol. 171:1520–1528. 2007.PubMed/NCBI
5	Fujimoto J, Yasui W, Tahara H and Tahara E, Kudo Y, Yokozaki H and Tahara E: DNA hypermethylation at the pS2 promoter region is associated with early stage of stomach carcinogenesis. Cancer Lett. 149:125–134. 2000. View Article : Google Scholar
6	Machado JC, Carneiro F, Ribeiro P, Blin N and Sobrinho-Simões M: pS2 protein expression in gastric carcinoma. An immunohistochemical and immunoradiometric study. Eur J Cancer. 32A:1585–1590. 1996. View Article : Google Scholar : PubMed/NCBI
7	Taupin D, Pedersen J, Familari M, Cook G, Yeomans N and Giraud AS: Augmented intestinal trefoil factor (TFF3) and loss of pS2 (TFF1) expression precedes metaplastic differentiation of gastric epithelium. Lab Invest. 81:397–408. 2001. View Article : Google Scholar
8	Taupin DR, Kinoshita K and Podolsky DK: Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc Natl Acad Sci USA. 97:799–804. 2000. View Article : Google Scholar
9	Yamachika T, Werther JL, Bodian C, et al: Intestinal trefoil factor: a marker of poor prognosis in gastric carcinoma. Clin Cancer Res. 8:1092–1099. 2002.PubMed/NCBI
10	Wong WM, Poulsom R and Wright NA: Trefoil peptides. Gut. 44:890–895. 1999. View Article : Google Scholar : PubMed/NCBI
11	Farrell JJ, Taupin D, Koh TJ, et al: TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury. J Clin Invest. 109:193–204. 2002. View Article : Google Scholar
12	Dhar DK, Wang TC, Maruyama R, et al: Expression of cytoplasmic TFF2 is a marker of tumor metastasis and negative prognostic factor in gastric cancer. Lab Invest. 83:1343–1352. 2003. View Article : Google Scholar : PubMed/NCBI
13	Kim H, Eun JW, Lee H, Nam SW, Rhee H, Koh KH and Kim KH: Gene expression changes in patient-matched gastric normal mucosa, adenomas, and carcinomas. Exp Mol Pathol. 90:201–209. 2011. View Article : Google Scholar
14	Hu GY, Yu BP, Dong WG, et al: Expression of TFF2 and Helicobacter pylori infection in carcinogenesis of gastric mucosa. World J Gastroenterol. 9:910–914. 2003.PubMed/NCBI
15	Shi SQ, Cai JT and Yang JM: Expression of trefoil factors 1 and 2 in precancerous condition and gastric cancer. World J Gastroenterol. 12:3119–3122. 2006.PubMed/NCBI
16	Paoletti X, Oba K, Burzykowski T, et al: Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 303:1729–1737. 2010. View Article : Google Scholar : PubMed/NCBI
17	Zhang Y, Yu G, Wang Y, et al: Activation of protease-activated receptor (PAR) 1 by frog trefoil factor (TFF) 2 and PAR4 by human TFF2. Cell Mol Life Sci. 68:3771–3780. 2011. View Article : Google Scholar
18	Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 4:844–847. 1998. View Article : Google Scholar : PubMed/NCBI
19	Liu SB, He YY, Zhang Y, et al: A novel non-lens betagamma-crystallin and trefoil factor complex from amphibian skin and its functional implications. PLoS One. 3:e17702008. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
21	Gratio V, Walker F, Lehy T, Laburthe M and Darmoul D: Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase. Int J Cancer. 124:1517–1525. 2009. View Article : Google Scholar
22	Moss SF, Lee JW, Sabo E, et al: Decreased expression of gastrokine 1 and the trefoil factor interacting protein TFIZ1/GKN2 in gastric cancer: influence of tumor histology and relationship to prognosis. Clin Cancer Res. 14:4161–4167. 2008. View Article : Google Scholar
23	Halldórsdóttir AM, Sigurdardóttrir M, Jónasson JG, et al: Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland. Dig Dis Sci. 48:431–441. 2003.
24	Yamaguchi H, Goldenring JR, Kaminishi M and Lee JR: Identification of spasmolytic polypeptide expressing metaplasia (SPEM) in remnant gastric cancer and surveillance postgastrectomy biopsies. Dig Dis Sci. 47:573–578. 2002. View Article : Google Scholar
25	Jones PA and Laird PW: Cancer epigenetics comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI
26	Peterson AJ, Menheniott TR, O’Connor L, et al: Helicobacter pylori infection promotes methylation and silencing of trefoil factor 2, leading to gastric tumor development in mice and humans. Gastroenterology. 139:2005–2017. 2010. View Article : Google Scholar